CompletedNCT01358357
Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex
Medication studyAges 18+Multiple countriesBipolarity
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Dothan, United States · Glendale, United States and 86 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJune 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 965
- Sponsor
- Sumitomo Pharma America, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Australia, France, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT01358357
- Official title
Show the full official title
A Randomized, Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Prevention of Recurrence in Subjects With Bipolar I Disorder
Recruitment & locations
CompletedDothan, United States · Glendale, United States · Los Angeles, United States
85 more locations
- Oceanside, United States
- Palo Alto, United States
- San Francisco, United States
- Santa Ana, United States
- Stanford, United States
- Bradenton, United States
- Jacksonville, United States
- Miami Springs, United States
- Orlando, United States
- Atlanta, United States
- Terre Haute, United States
- Haverhill, United States
- St Louis, United States
- New York, United States
- Rochester, United States
- Garfield Heights, United States
- Oklahoma City, United States
- Media, United States
- Lincoln, United States
- Charleston, United States
- Memphis, United States
- Dallas, United States
- Lake Jackson, United States
- Córdoba, Argentina
- Rosario, Argentina
- Buenos Aires, Argentina
- La Plata, Argentina
- Mendoza, Argentina
- Elizabeth Vale, Australia
- Malvern, Australia
- Richmond, Australia
- Fremantle, Australia
- Burgas, Bulgaria
- Plovdiv, Bulgaria
- Rousse, Bulgaria
- Sofia, Bulgaria
- Varna, Bulgaria
- Santiago, Chile
- Rijeka, Croatia
- Zagreb, Croatia
- Zagreg, Croatia
- Brno, Czechia
- Brno-Bohunice, Czechia
- Havířov, Czechia
- Písek, Czechia
- Prague, Czechia
- Prague 8-Bohunice, Czechia
- Přerov, Czechia
- Ústí nad Labem, Czechia
- Dijon, France
- Dole, France
- Montpellier, France
- Nîmes, France
- Budapest, Hungary
- Győr, Hungary
- Gyula, Hungary
- Shibukawa, Japan
- Sapporo, Japan
- Komagane, Japan
- Matsumoto-shi, Japan
- Sakai, Japan
- Kanzaki, Japan
- Kita-ku, Japan
- Aichi, Japan
- Hachioji, Tokyo, Japan
- Kumamoto, Japan
- Okinawa, Japan
- Toyama, Japan
- Gdynia, Poland
- Kielce, Poland
- Torun, Poland
- Tuszyn, Poland
- Wroclaw, Poland
- Izhevsk, Russia
- Nizhny Novgorod, Russia
- Saint Petersburg, Russia
- Tomsk, Russia
- Belgrade, Serbia
- Kragujevac, Serbia
- Niš, Serbia
- Novi Kneževac, Serbia
- Rimavská Sobota, Slovakia
- Zlaté Moravce, Slovakia
- Czechia
- Russia
Questions about this study
Who is behind this study?
The study sponsor is Sumitomo Pharma America, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Lurasidone and Placebo.
Who was this study for?
Listed age limits: from 18 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me